Sat.Jun 05, 2021 - Fri.Jun 11, 2021

article thumbnail

Digital fabric could be used to measure health data

pharmaphorum

Researchers in the US have developed a wearable fabric that can sense, store and analyse data that could be used to measure physiological functions or detect illness. The team from Massachusetts Institute of Technology (MIT) claim this is the first example of a fabric which can record data in a digital rather than in an analogue format, allowing it to be programmed like any other digital device.

article thumbnail

Phesi COVID-19 study indicates obesity a major complicating factor

Outsourcing Pharma

The virtual clinical development firmâs analysis of patient profiles reflects obesity is the most significant indicator for severity in those under 40.

114
114
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

The Rise of Audio Social Networks – Where Pharma Can Make an Impact

Pharma Marketing Network

Anyone with a smart device has been feeling the grueling effects of social isolation and screen fatigue since the start of the COVID-19 outbreak. Recently, we have witnessed a flood of new “audio-social apps” and audio features on social media platforms, aiming to finds new ways to connect, curb loneliness and cut excessive screen exposure. What are some of these audio-focused platforms and where can pharma play a role?

98
article thumbnail

“Ethno-pharma” Opportunities in India

Pharma Mirror

In the new normal scenario of Healthcare, where the approaches are patient-centric and no longer product-centric, traditional and integrative medicinal practices are rooting to the greater extent so does the ‘Ethno-pharmacy’ At the intersection of social and natural sciences, Ethno-pharmacy is a field that focuses on the traditional medicines (and pharmaceuticals) and the cultural determinants to investigate the possible use/perception of traditional medicines (and also pharmaceutica

52
article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

Ensuring accessibility: Crossing the digital divide in healthcare

pharmaphorum

“Rarely does the answer come from the boardroom” – what can user experience teach us about building accessible digital health? No one should be left behind as the world embraces digital healthcare say leading user experience voices. The experts discussed the benefits and merits of co-creation during a session on bridging the digital divide, held during the recent Patient Experience Digital Summit.

article thumbnail

Michael J. Fox Foundation shares Parkinson’s genetic data

Outsourcing Pharma

In partnership with 23andMe, the group has released a wealth of new de-identified data from the largest-ever Parkinsonâs cohort, to aid future research.

99

More Trending

article thumbnail

Robin Kamen

Pharma Marketing Network

Robin Kamen is an experienced innovator in digital strategy with a deep background in leadership positions for healthcare and consumer products companies. She has worked with many omnichannel brands to use digital marketing technologies to improve B2C and B2B customer engagement funnels and drive sales and retention. She is also skilled in developing the change management often needed to secure buy-in for and to successfully operate digital strategies.

52
article thumbnail

Trial finds Orion digital therapeutic helps chronic pain sufferers

pharmaphorum

A digital therapeutic aimed at people with chronic lower back pain based on virtual reality (VR) has shown encouraging results in a clinical trial, helping patients manage the fear of movement that can reduce their activity and impede recovery. The therapy uses a VR headset to guide people with chronic pain through a series of cognitive behavioural therapy (CBT) exercises that are designed to help them overcome the fear of movement – also known as kinesiophobia.

130
130
article thumbnail

FDA approves Biogen’s Alzheimer's drug, Aduhelm

Outsourcing Pharma

The US Food and Drug Administration (FDA) has approved Biogenâs Aduhelm (aducanumab) for the treatment of Alzheimerâs: making it the first new treatment approved for the disease since 2003.

FDA 98
article thumbnail

Medication Adherence and the Importance of Packaging

Lifewell Rx Pharmacy

According to a study published in the National Library of Medicine, medication non-adherence may lead to “worsening condition, increased comorbid diseases, increased health care costs, and death.” To prevent this, patients must work with a pharmacy to store prescriptions correctly. For example, packaging plays a vital role in promoting medication adherence.

article thumbnail

Position Your Pharmacy for Expansion

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

article thumbnail

Pharma Marketing Network 2021 Summer Summit: Evolving the Customer Experience

Pharma Marketing Network

Join PMN on July 15th for our premier event on Customer Experience, where we will discuss best practices for moving beyond buzzwords to elevate experience and drive true patient and provider engagement based on empathy and data insights. Hear from leading Experience and Omnichannel experts from Merck, BMS, Novartis, AstraZeneca, UCB, AbbVie, and more on winning strategies to transform data into actionable strategy, elevate CX beyond campaign optimization and activate the “Engagement Matrix” in y

52
article thumbnail

Keeping clinical trial data safe – handling cybersecurity in a risky world

pharmaphorum

The development of vaccines for COVID-19 has been a masterclass in effective collaboration and applied digitisation in healthcare. However the increased complexity and involvement of different parties, exposes manufacturers to heightened threat levels. Abel Archundia discusses how COVID-19 has highlighted the importance of securing clinical trials against cyber threats.

Vaccines 111
article thumbnail

Novo Nordisk weight-management drug lands FDA approval

Outsourcing Pharma

The pharmacy company's Wegovy (semaglutide) is the first therapy designated for chronic weight management that the agency has granted approval since 2014.

FDA 98
article thumbnail

Venlafaxine & Weight Gain? Can you gain weight?

Druggist

Venlafaxine & weight gain? The focus of this post is to explore evidence be one of the most common side effects of venlafaxine. Additionally, I will talk about other aspects of venlafaxine, including licensed use, and common side effects. What is Venlafaxine? Venlafaxine is an antidepressant drug used to treat major depression, general and social anxiety disorders and panic conditions (BNF, 2021).

52
article thumbnail

What the FDA's New Dosage Guidance Means for the Future of Clinical Research

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

article thumbnail

Tom Croce

Pharma Marketing Network

Tom Croce is vice president for global patient advocacy at bluebird bio, inc., the clinical-stage biotech company that develops gene therapies for severe genetic and rare diseases. He and his team are responsible for identification and integration of patient perspectives across the entire development and commercial continuum, while ensuring meaningful company representation to patient, caregiver and advocate partners around the world.

52
article thumbnail

Country focus: China & APAC’s growing medical needs bring opportunities and challenges

pharmaphorum

Dr Jay Mei from Antengene tells us how the Asia Pacific region is opening up to innovative pharma companies, and gives tips for companies navigating this enormous market. Home to over 60% of the world’s population, Asia Pacific (APAC) is not a region the biopharma industry can afford to ignore. Dr Jay Mei, founder and CEO of Antengene, notes that the region has rich innovation resources but also urgent medical needs, leading to both opportunities and uncertainties for the industry.

article thumbnail

Optimizing tablet manufacturing complex but vital: I Holland

Outsourcing Pharma

A leader from the manufacturing technology provider talks about how companies can work to streamline oral solid dose manufacturing to remain competitive.

79
article thumbnail

Telstar addresses the latest trends in aseptic process solutions at Achema Pulse 2021

Pharma Mirror

Terrassa (Barcelona): Telstar will be exhibiting the latest developments in aseptic technology for pharmaceutical production and integrated turnkey engineering & construction services for process facilities at Achema Pulse 2021. The company will be present at the digital flagship event of the global process industries during the whole of June and will be live during 15-16th June.

52
article thumbnail

5 Reasons to Upgrade Your Pharmacy Management Software

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

article thumbnail

Amicus' Pompe disease therapy joins early access scheme

Pharma Times

The MHRA has issued an EAMS scientific opinion opening the door to use of cipaglucosidase alfa with miglustat in eligible patients with Pompe disease

51
article thumbnail

ASCO21: Gilead sets up first FDA okay for adult ALL with Tecartus data

pharmaphorum

Novartis’ Kymriah has had the CAR-T therapy market for acute lymphoblastic leukaemia (ALL) to itself so far, but Gilead Sciences’ Kite subsidiary is now looming in the rear view mirror – armed with new data for its already-filed rival Tecartus. Results of the phase 1/2 ZUMA-3 trial of Tecartus (brexucabtagene autoleucel) reported at the ongoing ASCO conference revealed a 71% complete response rate with the CAR-T in heavily pre-treated adult patients with B-cell precursor ALL.

FDA 105
article thumbnail

Decentralized format can elevate research: Hawthorne Effect

Outsourcing Pharma

A leader from the virtual research solutions specialist discusses how a greater pushed toward home-based research can lead to a range of benefits.

61
article thumbnail

5 Ways the Right EPCR Software Can Benefit EMS Organizations

Pharma Mirror

Emergency medical response requires a coordinated effort. It’s a field that burdens people with the task of providing an organized and immediate medical response in an often chaotic and high-pressure environment. To be able to do this in a consistent and timely manner, many emergency medical services (EMS) providers rely on electronic patient care reports (ePCR) solutions. ePCR is critical to the operation of EMS organizations because it allows staff members and response coordinators to stay on

article thumbnail

MHRA approves Venclyxto for newly diagnosed AML

Pharma Times

The approval is based on results from the Phase III VIALE-A study as well as the Phase Ib M14-358 clinical trial

49
article thumbnail

Aduhelm approval could signal new era for CNS drugs; analysts

pharmaphorum

The unexpected approval and lofty pricing of Biogen’s Alzheimer’s therapy Aduhelm is clearly the biopharma event of the year so far, but what are the broader implications for the industry as a whole? Analysts at RBC Capital Markets say that the decision points to an unprecedented shift in position for the FDA when it comes to regulating drugs for neurological and psychiatric disorders – and while the potential for Aduhelm may still be speculative , other drug developers could see big

FDA 99
article thumbnail

BioCelerate, FDA forge nonclinical data partnership

Outsourcing Pharma

The two organizations have formed a public-private partnership aimed at improving nonclinical research through better practices and standardization.

FDA 52
article thumbnail

Pacira BioSciences, Inc. partners with Ashfield Engage to deliver European commercial infrastructure

Pharma Mirror

Ashfield Engage, part of UDG Healthcare plc, today announced that it has been selected by US-based Pacira BioSciences, Inc. to provide strategic commercialization services for its non-opioid pain management products in select European countries. Pacira has partnered with Ashfield Engage to develop a commercial strategy and deliver outsourced operations in numerous European countries, including the UK, Germany, Sweden, Austria, Netherlands and Finland.

52
article thumbnail

SMC backs five new medicines for NHS use

Pharma Times

Servier's Lonsurf and AstraZeneca's Calquence are among the positive decisions

49
article thumbnail

And then there were three: another FDA adcomm member quits over Aduhelm

pharmaphorum

The fallout over the FDA’s decision to approved Biogen’s Alzheimer’s therapy Aduhelm continues to be felt, with a third member of its advisory committee resigning in protest. . The latest to depart the FDA’s Peripheral and Central Nervous System Drugs panel is Aaron Kesselheim of Harvard Medical School, joining fellow committee members Joel Perlmutter and David Knopman who quit earlier this week.

FDA 98
article thumbnail

Update on FDA COVID-19 activity, advice, and action

Outsourcing Pharma

The US agencyâs latest actions and advice against the virus include information on test recalls, , approval and reauthorization of treatments, and more.

FDA 52
article thumbnail

Preparing For The BCMTMS Exam in 2021-2022

Med Ed 101

I get quite a few questions about preparing for the BCMTMS exam. I’ve been fortunate to receive feedback from many candidates now regarding our content and how to best tailor our educational approach. I’m happy with the testimonials that we have received that make me believe we provide the best resources on the market that […]. The post Preparing For The BCMTMS Exam in 2021-2022 appeared first on Med Ed 101.

article thumbnail

New research identifies single biomarker that can indicate underlying neurodegeneration

Pharma Times

Blood test can be used to identify the presence of a protein that can reveal underlying neurodegeneration

49
article thumbnail

FDA slammed over Aduhelm OK as Biogen takes heat for $56k price tag

pharmaphorum

The FDA “has failed in its responsibility to protect patients and families from unproven treatments with known harms” in approving Biogen’s Alzheimer’s disease drug Aduhelm. That was the damning conclusion of the influential Institute for Clinical and Economic Review (ICER) in the US to yesterday’s approval of Aduhelm (aducanumab), the first new treatment for Alzheimer’s since 2003, which it says has “no evidentiary basis.” Biogen meanwhile has bee

FDA 98
article thumbnail

Dutch biotech seeks out industry alliances to commercialize its ADC on back of trial results

Outsourcing Pharma

Dutch biotech, Byondis, today announced positive topline results from a Phase 3 study, which it says confirms the safety and efficacy of its antibody drug conjugate (ADC) - SYD985 - as a treatment for patients with pretreated HER2-positive locally advanced or metastatic breast cancer (MBC).

52